Paper22360481
Leishmaniasis: prevention, parasite detection and treatment.
Kobets T and 2 others. Curr Med Chem, 2012. Cited by 91 papers, by iCite.
Cite this record
ConductScience Library. Leishmaniasis: prevention, parasite detection and treatment. Papers, record 22360481. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22360481
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiprotozoal Agents | Major topic |
| Leishmania | Major topic |
| Leishmaniasis | Major topic |
| Protozoan Vaccines | Major topic |
| Animals | |
| DNA, Protozoan | |
| Enzyme-Linked Immunosorbent Assay | |
| Humans | |
| Microscopy | |
| Skin Tests | |
| Vaccines, DNA |
Source PubMed
Cited by48
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 91 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42860538 | Antileishmanial potential of polar fractions from Amaranthus blitoides S. Watson, Caucalis platycarpos L., and Cistanche flava (C.A.Mey.) Korsh.: evidence from in vitro and in vivo studies. | Trop Med Health | 2026 | https://conductscience.org/library/papers/42860538 | PubMed |
| 41164189 | Non-additive strong gene interactions cause striking differences in organ pathology and cytokine response in Leishmaniasis. | Front Immunol | 2025 | https://conductscience.org/library/papers/41164189 | PubMed |
| 40978352 | Identification of Tripeptide Inhibitors Targeting MAPK3 in Leishmania martiniquensis and Leishmania orientalis Using Molecular Modeling, Virtual Screening, Molecular Dynamics, and In Vitro Approach. | ACS Omega | 2025 | https://conductscience.org/library/papers/40978352 | PubMed |
| 40600021 | A Century of Epidemiological Advances in Cutaneous and Visceral Leishmaniasis in Algeria. | J Parasitol Res | 2025 | https://conductscience.org/library/papers/40600021 | PubMed |
| 40330482 | Improving reproducibility and translational potential of mouse models: lessons from studying leishmaniasis. | Front Immunol | 2025 | https://conductscience.org/library/papers/40330482 | PubMed |
| 39918617 | Evaluation of the Anti-Leishmanial Activity of the Hydroalcoholic Extract of Green Algae (Spirogyra): Investigation of Weight Indicators (Lesion Size and Organ Weights) in BALB/c Mice. | Acta Parasitol | 2025 | https://conductscience.org/library/papers/39918617 | PubMed |
| 39328317 | Diagnostic challenges in cutaneous leishmaniasis due to atypical Leishmania infantum: pathologists' insights from re-emergence zones. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/39328317 | PubMed |
| 38839916 | An integrated bioinformatic analysis of microarray datasets to identify biomarkers and miRNA-based regulatory networks in leishmaniasis. | Sci Rep | 2024 | https://conductscience.org/library/papers/38839916 | PubMed |
| 38003236 | In Silico Exploration of the Trypanothione Reductase (TryR) of L. mexicana. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38003236 | PubMed |
| 37631028 | Synthesis of 1,2,3-Triazole-Containing Methoxylated Cinnamides and Their Antileishmanial Activity against the Leishmania braziliensis Species. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37631028 | PubMed |
| 37600780 | Functionally distinct regions of the locus Leishmania major response 15 control IgE or IFNγ level in addition to skin lesions. | Front Immunol | 2023 | https://conductscience.org/library/papers/37600780 | PubMed |
| 37520195 | In vitro evaluation of herbal based Lesh Nat B cream against Leishmania tropica. | J Parasit Dis | 2023 | https://conductscience.org/library/papers/37520195 | PubMed |
| 37404482 | Evaluation of Renal Function Profile in Human Visceral Leishmaniasis (Kala-Azar) Patients: A Case of Western Tigray, Ethiopia. | Res Rep Trop Med | 2023 | https://conductscience.org/library/papers/37404482 | PubMed |
| 36559136 | Development of Ag-ZnO/AgO Nanocomposites Effectives for Leishmania braziliensis Treatment. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36559136 | PubMed |
| 36457781 | Cytotoxic screening and in vitro effect of sodium chlorite against Leishmania major promastigotes. | J Parasit Dis | 2022 | https://conductscience.org/library/papers/36457781 | PubMed |
| 35692473 | In vitro efficacy of polymer coated miltefosine drug against leishmania tropica. | J Parasit Dis | 2022 | https://conductscience.org/library/papers/35692473 | PubMed |
| 33776999 | Unraveling the Role of Immune Checkpoints in Leishmaniasis. | Front Immunol | 2021 | https://conductscience.org/library/papers/33776999 | PubMed |
| 33193363 | Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4+ T Effector and Regulatory T Cells in Cutaneous Leishmaniasis. | Front Immunol | 2020 | https://conductscience.org/library/papers/33193363 | PubMed |
| 32784933 | Nanoparticles Formulations of Artemisinin and Derivatives as Potential Therapeutics for the Treatment of Cancer, Leishmaniasis and Malaria. | Pharmaceutics | 2020 | https://conductscience.org/library/papers/32784933 | PubMed |
| 31991635 | Synthesis of Biologically Active Molecules through Multicomponent Reactions. | Molecules | 2020 | https://conductscience.org/library/papers/31991635 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22360481
GET https://conductscience.org/api/papers/v1/22360481/cited_by?page=2